/
AAPG
$17.70+$0.93 (+5.55%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6B
93M shares
52-week range
$16.36 – $48.45
4% from low
Exchange
NASDAQ
ADRC
Borrow rate
43.80%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$0.45
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $14.5M | $12.4M | $27.9M | $209.7M | $222.0M | $980.6M | $558.5M |
| Cost of revenue | $0 | $2.1M | $2.0M | $3.3M | $22.0M | $30.5M | $29.1M | $131.7M |
| Gross profit | $6.8M | $12.4M | $10.5M | $24.6M | $187.7M | $191.4M | $951.6M | $426.7M |
| Gross margin | 100.0% | 85.6% | 84.2% | 88.1% | 89.5% | 86.2% | 97.0% | 76.4% |
| R&D | $249.6M | $463.9M | $564.6M | $766.5M | $743.1M | $707.0M | $947.2M | $1.08B |
| Operating income | −$345.4M | −$582.7M | −$663.9M | −$869.8M | −$849.8M | −$872.6M | −$369.7M | −$1.18B |
| EBITDA | −$326.3M | −$1.47B | −$652.2M | −$798.3M | −$787.0M | −$743.6M | −$237.6M | −$1.10B |
| Net income | −$345.3M | −$1.48B | −$677.6M | −$782.4M | −$882.9M | −$925.6M | −$405.4M | −$1.21B |
| Net margin | -5072.8% | -10202.7% | -5442.6% | -2803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
| EPS (diluted) | -26.68 | -112.04 | -50.24 | -49.12 | -53.60 | -52.48 | -5.36 | -13.56 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $938M | $-7.06 | $-14.48–$-3.16 | 5 |
| 2027 | $1.6B | $-2.70 | $-13.18–$7.19 | 4 |
| 2028 | $2.4B | $-1.59 | $-3.23–$-0.79 | 3 |
| 2029 | $3.0B | $-4.18 | $-8.47–$-2.07 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
www.ascentage.cn- Employees
- 767
- IPO / List date
- Jan 24, 2025
Held by traders on TradeandTell
No one on the platform currently holds AAPG.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AAPG as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2003-04-07 | 3-for-1 |
Recent trades on TradeandTell
No one on the platform has traded AAPG yet.